Cardiol Therapeutics (TSE:CRDL) Releases Quarterly Earnings Results

Cardiol Therapeutics (TSE:CRDL – Get Free Report) issued its quarterly earnings results on Monday. The company reported C($0.10) earnings per share for the quarter, FiscalAI reports.

Cardiol Therapeutics Stock Performance

Shares of TSE CRDL traded up C$0.03 during mid-day trading on Monday, hitting C$1.83. 70,917 shares of the company were exchanged, compared to its average volume of 115,746. The company has a quick ratio of 6.84, a current ratio of 4.16 and a debt-to-equity ratio of 0.70. The stock has a 50 day simple moving average of C$1.68 and a 200-day simple moving average of C$1.52. Cardiol Therapeutics has a 1-year low of C$1.23 and a 1-year high of C$2.33. The firm has a market cap of C$204.37 million, a price-to-earnings ratio of -4.69 and a beta of 0.24.

Get Cardiol Therapeutics alerts:

About Cardiol Therapeutics

(Get Free Report)

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Featured Articles

• Five stocks we like better than Cardiol Therapeutics
• Before the Moon Base Gets Built, These 4 Companies Win
• Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
• 3 Stocks That Win If Inflation Surprises to the Downside
• MercadoLibre Boldly Invests in Growth: Discount Deepens

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.